2023
Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approach
2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2017
Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine
Greenwood B, Dicko A, Sagara I, Zongo I, Tinto H, Cairns M, Kuepfer I, Milligan P, Ouedraogo J, Doumbo O, Chandramohan D. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malaria Journal 2017, 16: 182. PMID: 28464937, PMCID: PMC5414195, DOI: 10.1186/s12936-017-1841-9.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria vaccineTransmission seasonEffective malaria control measuresEffective immunological memoryMalaria transmission seasonHigh transmission seasonMass vaccination campaignMalaria control measuresHigh initial efficacyMalaria chemopreventionSeasonal vaccinationSulfadoxine-pyrimethamineMalaria infectionMalaria treatmentImmunological memoryPilot implementation projectVaccination campaignInitial efficacyFull courseMalaria transmissionVaccineEuropean Medicines AuthorityHealthcare giversMajor cause
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150